

# References

---

## REFERENCES

- Abdelmalek MF, Firpi RJ, Soldevila-Pico C, Reed AI, Hemming AW, Liu C, Crawford JM, Davis GL, Nelson DR (2004):* Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. *Liver Transpl*; 10: 199-207.
- Alavez-Ramirez J, Fuentes-Allen JL, López-Estrada J (2011):* Noninvasive monitoring of hepatic damage from hepatitis C virus infection. *Comput Math Methods Med*: 325470.
- Alnaes MS, Isaksen J, Mardal KA, Romner B, Morgan MK, Ingebrigtsen T (2007):* Computation of hemodynamics in the circle of Willis. *Stroke*; 38(9): 2500-2505.
- Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS (1999):* The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. *N Engl J Med*; 341(8): 556-562.
- Arends JE, Stuart JC, Baak LC, van der Ende ME, Van Erpecum KJ, Simons CP, Boland GJ, van Baarle D, Hoepelman AI (2009):* Plasma HCV-RNA decline in the first 48 h identifies hepatitis C virus mono-infected but not HCV/HIV-coinfected patients with an undetectable HCV viral load at week 4 of peginterferon-alfa-2a/ribavirin therapy. *J. Viral. Hepat*; 16(12): 867–875.
- Bekkering FC, Neumann AU, Brouwer JT, Levi-Drummer RS, Schalm SW (2001):* Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis C patients: a case control study. *BMC Gastroenterol*; 1-14.
- Bellomo N, Li NK, Maini PK (2008):* On the foundations of cancer modelling: Selected topics, speculations, and perspectives. *Math model method appl sci*; 18(4): 593-646.

## References

---

- Bender EA (2000):** An Introduction to Mathematical Modeling. Dover, New York.
- Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, Wiedenmann B, Hopf U, Zeuzem S (2003):** Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. *Hepatology*; 37: 600–609.
- Berg T, Von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T, Rasenack J, Pape GR, Schmidt WE, Kallinowski B, Klinker H, Spengler U, Martus P, Alshuth U, Zeuzem S (2006):** Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. *Gastroenterology*; 130(4): 1086-1097.
- Bertotti ML and Delitala M (2004):** From discrete kinetic and stochastic game theory to modelling complex systems in applied sciences. *Math. Models Methods Appl*; 14: 1061-1084.
- Bini EJ, Brau N, Currie S, Shen H, Anand BS, Hu KQ, Jeffers L, Ho SB, Johnson D, Schmidt WN, King P, Cheung R, Morgan TR, Awad J, Pedrosa M, Chang KM, Aytaman A, Simon F, Hagedorn C, Moseley R, Ahmad J, Mendenhall C, Waters B, Strader D, Sasaki AW, Rossi S, Wright TL (2005):** Prospective multicenter study of eligibility for antiviral therapy among 4, 084 U.S. veterans with chronic hepatitis C virus infection. *Am J Gastroenterol*; 100(8): 1772-1779.
- Blight KJ, Kolykhalov AA, Rice CM (2000):** Efficient initiation of HCV RNA replication in cell culture. *Science*; 290: 1972–1974.

# References

---

- Bortoletto G, Realdon S, Dal Pero F (2007):** Insulin resistance (IR) defined by the homeostasis model of assessment insulin resistance (HOMA-IR) index has a direct effect on early viral kinetics during pegylated-interferon therapy for chronic hepatitis C. *Hepatology*; 46: 361A.
- Boulestin A, Kamar N, Sandres-Sauné K, Legrand-Abravanel F, Alric L, Vinel JP, Rostaing L, Izopet J (2006):** Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon. *J. Med. Virol*; 78: 365–371.
- Carrejo DJ and Marshall J (2007):** What is Mathematical Modelling? Exploring Prospective Teachers' Use of Experiments to Connect Mathematics to the Study of Motion. *Mathematics Education Research Journal*; 19(1): 45–76.
- Chu CM, Yeh CT, Liaw YF (1999):** Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus. *Gut*; 45(4): 613-617.
- Clayton RH and Panfilov AV (2008):** A guide to modelling cardiac electrical activity in anatomically detailed ventricles. *Prog Biophys Mol Biol*; 96(1-3): 19-43.
- Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C (2001):** Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. *J Viral Hepat*; 8: 87-95.
- Colombatto P, Civitano L, Oliveri F, Coco B, Ciccorossi P, Flichman D, Campa M, Bonino F, Brunetto MR (2003):** Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase. *Antivir Ther*; 8: 519–530.

## References

---

- Cooper C, Lawitz EJ, Ghali P, Rodriguez-Torres M, Anderson FH, Lee SS, Proulx L (2007):* Antiviral activity of the non-nucleoside polymerase inhibitor, VCH-759, in chronic hepatitis C patients: results from a randomized, doubleblind, placebo-controlled, ascending multiple dose study. *Hepatology*; 46 (1): 864A.
- Cormier EG, Tsamis F, Kajumo F, Durso RJ, Gardner JP, Dragic T (2004):* CD81 is an entry coreceptor for hepatitis C virus. *Proc Natl Acad Sci USA*; 101(19): 7270-7274.
- Cotler SJ, Layden JE, Neumann AU, Jensen DM (2003):* First phase hepatitis c viral kinetics in previous nonresponder patients. *J Viral Hepat*; 10(1): 43–49.
- Dahari H, Feliu A, Garcia-Retortillo M, Fornis X, Neumann AU (2005a):* Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. *J Hepatol*; 42: 491–498.
- Dahari H, Major M, Zhang X, Mihalik K, Rice CM, Perelson AS, Feinstone SM, Neumann AU (2005b):* Mathematical modeling of primary hepatitis C infection: Noncytolytic clearance and early blockage of virion production. *Gastroenterology*; 128: 1056–1066.
- Dahari H and Perelson AS (2007):* Hepatitis C virus RNA kinetics: Drug efficacy and the rate of HCV-infected cells loss. *World J Gastroenterol*; 13: 3020–3021.
- Dahari H, Ribeiro RM, Perelson AS (2007a):* Triphasic decline of hepatitis C virus RNA during antiviral therapy. *Hepatology*; 46(1): 16–21.

## References

---

- Dahari H, Lo A, Ribeiro RM, Perelson AS (2007b):*** Modeling hepatitis C virus dynamics: Liver regeneration and critical drug efficacy. *J Theor Biol*; 247(2): 371–381.
- Dahari H, Layden-Almer JE, Perelson AS, Layden TJ (2008):*** Hepatitis C viral kinetics in special populations. *Curr Hepat*; 7(3): 97-100.
- Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, Raknerud N, Bell H (2004):*** Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. *Hepatology*; 40(6): 1260-1265.
- Dalgard O, Bjoro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, Reichard O, Myrvang B, Sundelöf B, Ritland S, Hellum K, Frydén A, Florholmen J, Verbaan H (2008):*** Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. *Hepatology*; 47(1): 35-42.
- Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J (2003):*** Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. *Hepatology*; 38(3): 645–652.
- Delwaide J, El Saouda R, Gerard C, Belaiche J (2005):*** Hepatitis C infection: eligibility for antiviral therapies. *Eur J Gastroenterol Hepatol*; 17(11): 1185-1189.
- Desmond CP, Roberts SK, Dudley F, Mitchell J, Day C, Nguyen S, Pianko S (2006):*** Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. *J Viral Hepat*; 13: 311-315.

## References

---

- Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS (2004):** Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. *Nature*; 432: 922–924.
- Dougan JD (1994):** Callistell's the organization of learning: this is not creation science. *Journal of the experimental analysis of behaviour*; 62: 435-444.
- Drusano GL and Preston SL (2004):** A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. *J Infect Dis*; 189(6): 964-970.
- Durante-Mangoni E, Zampino R, Portella G, Adinolfi LE, Utili R, Ruggiero G (2009):** Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment. *Clin. Infect. Dis*; 49: 406–498.
- El-Katsha S, Labeeb S, Watts S, Younis A (2006):** Informal health providers and the transmission of hepatitis C virus: pilot study in two Egyptian villages. *East Mediterr Health J*; 12: 758–767.
- El-Zanaty, Fatma and Ann Way (2009):** Egypt Demographic and Health Survey 2008. Cairo, Egypt: Ministry of Health, El-Zanaty and Associates, and Macro International.
- Esteban JI, Sauleda S, Quer J (2008):** The changing epidemiology of hepatitis C virus infection in Europe. *J Hepatol* ; 48: 148-162.
- Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C (2005):** Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. *Hepatology*; 42: 255–262.

## References

---

*Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C; HALT-C Trial Group (2006):* Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. *Hepatology*; 44(6): 1675–1684.

*Ferenci P, Brunner H, Nachbaur K, Datz C, Gschwantler M, Hofer H, Stauber R, Hackl F, Jessner W, Rosenbeiger M, Munda-Steindl P, Hegenbarth K, Gangl A, Vogel W (2001):* Combination of interferon induction therapy and ribavirin in chronic hepatitis C. *Hepatology*; 34(5): 1006–1011.

*Ferenci P, Fried MA, Chaneac M (2003):* A dynamic model to predict sustained virological response to combination peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®) therapy in patients with chronic hepatitis C. Poster presented at the 54th Annual Meeting of the American Association for the Study of Liver Disease.

*Ferenci P (2004):* Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies *Journal of Antimicrobial Chemotherapy*; 53: 15–18.

*Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Gonçalves FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxì A, Chaneac M, Reddy KR (2005):* Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. *J Hepatol* 43(3): 425–433.

## References

---

- Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B, Datz C, Löschenberger K, Formann E, Staufer K, Steindl-Munda P, Austrian Hepatitis Study Group (2008):** Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. *Gastroenterology*; 135: 451–458.
- Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, Abdel-Wahab Y, Aly Ohn ES, Anwar W, Sallam I (2000):** The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. *Lancet*; 355: 887–891.
- Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçalves FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002):** Peginterferon alfa- 2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med*; 347: 975–982.
- Fried MW, Hadziyannis SJ, Shiffman M, Messinger D, Zeuzem S (2008):** Rapid viral response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis c virus infection. *J Hepatol* 48 (Suppl. 2): 5A..
- Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, Rimola A, Rodes J (2002):** Hepatitis C virus kinetics during and immediately after liver transplantation. *Hepatology*; 35(3): 680–687.
- Ghany MG, Strader DB, Thomas DL, Seeff LB (2009):** AASLD(American Association for the Study of Liver Diseases); diagnosis, management, and treatment of hepatitis C. *Hepatology*; 49: 1335-1374.



## References

---

**Hadziyannis SJ, Sette Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group (2004):** Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med*; 140(5): 346-355.

**Halfon P, Munteanu M, Poynard T (2008):** FibroTest-ActiTest as a non-invasive marker of liver fibrosis. *Gastroenterol Clin Biol* 32(6): 22–39.

**Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S (2003):** Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. *Hepatology* 37(6): 1351–1358.

**Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M (1995):** Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. *Nature*; 373(6510): 123–126.

**Hofmann WP and Zeuzem S (2011):** A new standard of care for the treatment of chronic HCV infection. *Nat Rev Gastroenterol Hepatol*; 8(5): 257-264.

**Hoofnagle JH, Wahed AS, Brown RS JR, Howell CD, Belle SH; Virahep-C Study Group (2009):** Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection. *J Infect Dis*; 199(8): 1112-1120.

**Houghton M (2009):** The long and winding road leading to the identification of the hepatitis C virus. *J Hepatol*; 51(5): 939-948.

## References

---

- Iacobellis A, Siciliano M, Perri F, Annicchiarico BE, Leandro G, Caruso N, Accadia L, Bombardieri G, Andriulli A (2007):*** Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. *J Hepatol*; 46(2): 206–212.
- Indolfi G and Resti M (2009):*** Perinatal transmission of hepatitis C virus infection. *Journal of medical virology*; 81(5): 836-843.
- Inoue K, Umehara T, Ruegg UT, Yasui F, Watanabe T, Yasuda H, Dumont JM, Scalfaro P, Yoshida M, Kohara M (2007):*** Evaluation of a cyclophilin inhibitor in hepatitis C virus infected chimeric mice in vivo. *Hepatology*; 45(4): 921–928.
- Jacobson IM, Brown RS Jr, Freilich B, Afdhal N, Kwo PY, Santoro J, Becker S, Wakil AE, Pound D, Godofsky E, Strauss R, Bernstein D, Flamm S, Pauly MP, Mukhopadhyay P, Griffel LH, Brass CA (2007):*** Peginterferon alfa-2b and weight-based or flatdose ribavirin in chronic hepatitis C patients: a randomized trial. *Hepatology*; 46(4): 971-981.
- Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B (2006):*** Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. *Hepatology*; 43(5): 954-960.
- Jessner W, Gschwantler M, Steindl-Munda P, Hofer H, Watkins-Riedel T, Wrba F, Mueller C, Gangl A, Ferenci P (2001):*** Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. *Lancet* 358: 1241–1242.

## References

---

- Jessner W, Stauber R, Hackl F, Datz C, Watkins-Riedel T, Hofer H, Gangl A, Kessler H, Ferenci P (2003):** Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection. *Journal of Viral Hepatitis* (1): 37–42.
- Kamal SM, El Kamary SS, Shardell MD, Hashem M, Ahmed IN, Muhammadi M, Sayed K, Moustafa A, Hakem SA, Ibrahiem A, Moniem M, Mansour H, Abdelaziz M (2007):** Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. *Hepatology*; 46: 1732-1740.
- Kamal SM (2011):** Hepatitis C virus genotype 4 therapy: progress and challenges. *Liver Int*; 31(1): 45-52.
- Kau A, Vermehren J, Sarrazin C (2008):** Treatment predictors of a sustained virologic response in hepatitis B and C. *J of Hepatology*(49); 634–651.
- Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Kwong AD, Zeuzem S (2007):** Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. *Hepatology*; 46: 631-639.
- Kohaar I, Ploss A, Korol E, Mu K, Schoggins J, O'Brien T, Rice C, Prokunina-Olsson L (2010):** Splicing diversity of the human OCLN gene and its biological significance for hepatitis C virus entry. *Journal of virology* 84 (14): 6987–6994.
- Lam NP, Pitrak D, Speralakis R, Lau AH, Wiley TE, Layden TJ (1997):** Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C. *Dig Dis Sci*; 42(1): 178–185.

## References

---

- Lauer GM and Walker BD (2001):** Hepatitis C virus infection. *N Engl J Med*; 345(1): 41-52.
- Layden JE, Layden TJ, Reddy KR, Levy-Drummer RS, Poulakos J, Neumann AU (2002):** First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. *J Viral Hepat*; 9(5): 340–345.
- Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ (2003):** Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. *Hepatology*; 37(6): 1343–1350.
- Layden-Almer JE, Cotler SJ, Layden TJ (2006):** Viral kinetics in the treatment of chronic hepatitis C. *J. Viral. Hepat*; 13: 499–504.
- Lee SR, Kardos KW, Schiff E, Berne CA, Mounzer K, Banks AT, Tatum HA, Friel TJ, Demicco MP, Lee WM, Eder SE, Monto A, Yearwood GD, Guillon GB, Kurtz LA, Fischl M, Unangst JL, Kriebel L, Feiss G, Roehler M (2011):** Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. *J Virol Methods*; 172(1-2): 27-31.
- Lefkowitz JH (2010):** Scheuer's Liver Biopsy Interpretation, 8e.
- Lemon SM, McKeating JA, Pietschmann T, Frick DN, Glenn JS, Tellinghuisen TL, Symons J, Furman PA (2010):** Development of novel therapies for hepatitis C. *Antiviral Res*; 86(1): 79-92.
- Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH (2000):** Pathogenesis, natural history, treatment, and prevention of hepatitis C. *Ann Intern Med*; 132: 296-305.

## References

---

- Lin K, Perni RB, Kwong AD, Lin C (2006):** VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. *Antimicrob Agents Chemother*; 50(5): 1813-1822.
- Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM (2005):** Complete replication of hepatitis C virus in cell culture. *Science* 309(5734): 623-626.
- Lindh M, Alestig E, Arnholm B, Eilard A, Hellstrand K, Lagging M, Wahlberg T, Wejstal R, Westin J, Norkrans G (2007):** Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection. *J Clin Microbiol*; 45(8): 2439–2445.
- Malcolm BA, Liu R, Lahser F, Agrawal S, Belanger B, Butkiewicz N, Chase R, Gheyas F, Hart A, Hesk D, Ingravallo P, Jiang C, Kong R, Lu J, Pichardo J, Prongay A, Skelton A, Tong X, Venkatraman S, Xia E, Girijavallabhan V, Njoroge FG (2006):** SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. *Antimicrob Agents Chemother*; 50(3): 1013–1020.
- Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annesse M, Romano M, Zechini F, Sogari F, Spirito F, Andriulli A (2005):** Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. *N Engl J Med*; 352(25): 2609-2617.
- Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, Vinelli F, Scotto G, Montalto G, Romano M, Cristofaro G, Mottola L, Spirito F, Andriulli A (2008):** Individualized Treatment Duration for Hepatitis C Genotype 1 Patients: A Randomized Controlled Trial, *Hepatology*; 47(1): 43-50.

## References

---

**Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001):** Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* ; 358(9286): 958-965.

**McCown MF, Rajyaguru S, Le Pogam S, Ali S, Jiang WR, Kang H, Symons J, Cammack N, Najera I (2008):** The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. *Antimicrob Agents Chemother*; 52(5): 1604-1612.

**McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo K, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK (2002):** Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. *Gastroenterology*; 123: 1061–1069.

**McHutchison JG (2004):** Understanding hepatitis C. *Am J Manag Care* 10(2 Suppl): S21-9.

**Medeiros-Filho JE, de Carvalho Mello IM, Pinho JR, Neumann AU, de Mello Malta F, da Silva LC, Carrilho FJ (2006):** Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy. *World J Gastroenterol*; 12(45): 7271–7277.

**Miller FD and Abu-Raddad LJ (2010):** Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. *Proc Natl Acad Sci USA*; 107(33): 14757-14762.

**Morota K, Fujinami R, Kinukawa H, Machida T, Ohno K, Saegusa H, Takeda K (2009):** A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen. *J Virol Methods*; 157: 8-14.

## References

---

- Munteanu M, Messous D, Ngo Y, Charlotte F, Imbert-Bismut F, Thabut D, Lebray P, Thibault V, Benhamou Y, Moussalli J, Ratziu V, Poynard T (2006):* A prospective analysis of the prognostic value of biomarkers (Fibro Test) in patients with chronic hepatitis C. *Clinical Chemistry*; 52(10): 1887–1896.
- Mushayabasa S and Bhunu CP (2011):* Epidemiological consequences of non-compliance to HCV therapy among IDUs. *International Journal of Research and Reviews in Applied Sciences*; 8(3): 2076-7366.
- National Institutes of Health Consensus Development Conference Statement (2002):* Management of hepatitis C. *Hepatology*; 36: S3-S20.
- Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS (1998):* Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. *Science*; 282(5386): 103–107.
- Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP, Perelson AS, Layden TJ (2000):* Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. *J Infect Dis*; 182: 28-35.
- Neumann AU, Mohan P, Lutchman G, Narkewicz M, Mollewon JP, Lopez-Talavera JC, Liang TJ, Schwarz KB (2004):* Hepatitis C viral kinetics in children treated with PegIFN alfa-2a. *Hepatology*(4); A712
- Nguyen TT, Sedghi-Vaziri A, Wilkes LB, Mondala T, Pockros PJ, Lindsay KL, McHutchison JG (1996):* Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. *J Viral Hepat*; 2: 75–78.

## References

---

- Noble D (2002):** The rise of computational biology. *Nat Rev Mol Cell Biol*; 3(6): 459-463.
- Nomura H, Miyagi Y, Tanimoto H, Higashi M, Ishibashi H (2009):** Effective prediction of outcome of combination therapy with pegylated interferon alpha 2b plus ribavirin in Japanese patients with genotype-1 chronic hepatitis C using early viral kinetics and new indices. *J. Gastroenterol*; 44: 338–345.
- Op De Beeck A and Dubuisson J (2003):** Topology of hepatitis C virus envelope glycoproteins. *Rev. Med. Virol*; 13(4): 233–241.
- Padmanabhan P and Dixit NM (2011):** Mathematical model of viral kinetics in vitro estimates the number of E2-CD81 complexes necessary for hepatitis C virus entry. *PLoS Comput Biol*; 7(12): e1002307.
- Pal S, Shuhart MC, Thomassen L, Emerson SS, Su T, Feuerborn N, Kae J, Gretch DR (2006):** Intrahepatic hepatitis C virus replication correlates with chronic hepatitis C disease severity in vivo. *J Virol*; 80(5): 2280–2290.
- Parruti G, Polilli E, Sozio F, Cento V, Pieri A, Di Masi F, Mercurio F, Tontodonati M, Mazzotta E, Ceccherini-Silberstein F, Manzoli L, Perno CF (2010):** Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin. *Antiviral Res*; 88(1): 124-127.
- Patel K, Muir AJ, McHutchison JG (2006):** Diagnosis and treatment of chronic hepatitis C infection *BMJ*; 332: 1013-1017.
- Pawlotsky JM (2002):** Use and interpretation of virological tests for hepatitis C. *Hepatology*; 36(Suppl 1): S65– 73.



## References

---

- Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G, Lonjon I, Castera L, Dhumeaux D (2004):* Antiviral action of ribavirin in chronic hepatitis C. *Gastroenterology*; 126(3): 703-714.
- Pascu M, Martus P, Höhne M, Wiedenmann B, Hopf U, Schreier E, Berg T (2004):* Sustained virologic response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. *Gut*; 53: 1345–1351.
- Pearlman BL, Ehleben C, Saifee S (2007):* Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. *Hepatology*; 46: 1688-1694.
- Perelson AS (2002):* Modelling viral and immune system dynamics. *Nat Rev Immunol*; 2(1): 28-36.
- Pilli M, Zerbini A, Penna A, Orlandini A, Lukasiewicz E, Pawlotsky JM, Zeuzem S, Schalm SW, von Wagner M, Germanidis G, Lurie Y, Esteban JI, Haagmans BL, Hezode C, Lagging M, Negro F, Homburger Y, Neumann AU, Ferrari C, Missale G; DITTO-HCV Study Group (2007):* HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). *Gastroenterology*; 133(4): 1132–1143.
- Pinzani M, Vizzutti F, Arena U, Marra F (2008):* Noninvasive assessment of liver fibrosis by biochemical scores and elastography. *Nat Clin Pract Gastroenterol Hepatol*; 5: 95–106.

## References

---

- Pischke S, Cornberg M, Manns MP (2008):* Hepatitis associated cryoglobulinemia. *Internist(Berl)*; 49(3): 297-304.
- Powers KA, Dixit NM, Ribeiro RM, Golia P, Talal AH, Perelson AS (2003):* Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. *Semin Liver Dis*; 23(Suppl 1): 13–18.
- Powers KA, Ribeiro RM, Patel K, Pianko S, Nyberg L, Pockros P, Conrad AJ, McHutchison J, Perelson AS (2006):* Kinetics of hepatitis C virus reinfection after liver transplantation. *Liver Transpl*; 12(2): 207–216.
- Rantala M and Van de Laar MJ (2008):* Surveillance and epidemiology of hepatitis B and C in Europe-a review. *Euro Surveill*; 13.
- Reed MC (2004):* Why is mathematical biology so hard? *Notices of the AMS* 51: 338-342.
- Ribeiro RM, Layden-Almer J, Powers KA, Layden TJ, Perelson AS (2003):* Dynamics of alanine aminotransferase during hepatitis C virus treatment. *Hepatology*; 38(2): 509–517.
- Roberts SK, Cooksley G, Dore GJ, Robson R, Shaw D, Berns H, Hill G, Klumpp K, Najera I, Washington C (2008):* Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. *Hepatology*; 48(2): 398-406.

## References

---

- Rong L and Perelson AS (2010):** Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling. *Crit Rev Immunol*; 30(2): 131-148.
- Sanchez-Tapias JM, Diago M, Escartín P, Enríquez J, Romero-Gómez M, Bárcena R, Crespo J, Andrade R, Martínez-Bauer E, Pérez R, Testillano M, Planas R, Solá R, García-Bengoechea M, Garcia-Samaniego J, Muñoz-Sánchez M, Moreno-Otero R (2006):** Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. *Gastroenterology*; 131: 451-460.
- Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK, Hussain M, Shah A, Cutler D, Zhang J, Zeuzem S (2007):** SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. *Gastroenterology*; 132(4): 1270-1278.
- Schiano TD, Gutierrez JA, Walewski JL, Fiel MI, Cheng B, Bodenheimer H Jr, Thung SN, Chung RT, Schwartz ME, Bodian C, Branch AD (2005):** Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. *Hepatology*; 42(6): 1420–1428.
- Scott JD and Gretch DR (2007):** Molecular diagnostics of hepatitis C virus infection: a systematic review. *Jama* 297(7): 724-732.
- Shepard CW, Finelli L, Alter MJ (2005):** Global epidemiology of hepatitis C virus infection. *Lancet Infect. Dis*; (5): 558–567.
- Shiffman ML, Salvatore J, Hubbard S, Price A, Sterling RK, Stravitz RT, Luketic VA, Sanyal AJ (2007):** Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. *Hepatology*; 46(2): 371-379.

## References

---

- Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, Umemura T, Ichijo T, Yoshizawa K, Kiyosawa K, Tanaka E, Nagano Interferon Treatment Research Group (2008):* Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. *Hepatology*; 48: 1753–1760.
- Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A (2005):* Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. *Hepatology*; 42: 962-973.
- Stoszek SK, Abdel-Hamid M, Narooz S, El Daly M, Saleh DA, Mikhail N, Kassem E, Hawash Y, El Kafrawy S, Said A, El Batanony M, Shebl FM, Sayed M, Sharaf S, Fix AD, Strickland GT(2006):* Prevalence of and risk factors for hepatitis C in rural pregnant Egyptian women. *Trans R Soc Trop Med Hyg*; 100: 102–107.
- Talal AH, Ribeiro RM, Powers KA, Grace M, Cullen C, Hussain M, Markatou M, Perelson AS (2006):* Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfecting sustained virological responders from nonresponders. *Hepatology*; 43(5): 943–953.
- Thiel HJ, Collett MS, Gould EA, Fauquet CM, Mayo MA, Maniloff J (2005):* VIIIth Report of the International Committee on Taxonomy of Viruses. San Diego: Academic Press; 979-996.
- Torriani FJ, Ribeiro RM, Gilbert TL, Schrenk UM, Clauson M, Pacheco DM, Perelson AS (2003):* Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. *J Infect Dis*; 188(10): 1498–1507.

## References

---

- Verma B, Ray SK, Srivastava RN (1981):** Mathematical models and their applications in medicine and health. *Health Popul Perspect Issues*; 4(1): 42-58.
- Villano S, Howe A, Raible D, Harper D, Speth J, Bichier G (2006):** Analysis of HCV NS5B genetic variants following monotherapy with HCV-796, a non-nucleoside polymerase inhibitor, in treatment-naïve HCV-infected patients. *Hepatology*; 44 1: 607A.
- Von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, Bergk A, Bernsmeier C, Häussinger D, Herrmann E, Zeuzem S (2005):** Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. *Gastroenterology*; 129(2): 522-527.
- Wasley A and Alter MJ (2000):** Epidemiology of hepatitis C: Geographic differences and temporal trends. *Semin Liver Dis*; 20: 1-16.
- Wasley A, Grytdal S, Gallagher K (2008):** Surveillance for acute viral hepatitis. *MMWR Surveill Summ*; 57: 1-24.
- Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH (1995):** Viral dynamics in human immunodeficiency virus type 1 infection. *Nature*; 373(6510): 117–122.
- Westin J, Lagging M, Dhillon AP, Norkrans G, Romero AI, Pawlotsky JM, Zeuzem S, Schalm SW, Verheij-Hart E, Negro F, Missale G, Neumann AU, Hellstrand K; DITTO-HCV Study Group (2007):** Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. *J Viral Hepat*; 14(1): 29–35.

## References

---

**Whishaw IQ, Hines DJ, Wallace DG (2001):** Dead reckoning (path integration) requires the hippocampal formation: evidence from spontaneous exploration and spatial learning tasks in light (allothetic) and dark (idiothetic) tests. *Behav Brain Res*; 127(1-2): 49-69.

**Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, Chiu CF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL (2007):** A randomized study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. *Gut* 56(4): 553-559.

**Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF (2011):** Hepatitis C virus entry into hepatocytes: Molecular mechanisms and targets for antiviral therapies. *J Hepatol*; 54(3): 566-576.

**Zeuzem S (2001):** The kinetics of hepatitis c virus infection. *Clinics in Liver Disease - Volume 5, Issue 4.*

**Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, Colucci G, Roth WK (2001) :** Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha 2a. *Gastroenterology* 120(6): 1438–1447.

**Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, Ibranyi E, Weiland O, Noviello S, Brass C, Albrecht J (2006):** Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. *J Hepatol*; 44(1): 97-103.